Anavex secures cash to study Anavex 2-73 for Rett syndrome
January 19, 2017Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex 2-73.
Rett Syndrome Foundation, which works as Rrettsyndrome.org, has granted $0.6 million for the study which is set to kick off this year, and to last three months.
Anavex said that primary and secondary endpoints include safety as well as Rett syndrome conditions such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. Pre-clinical research suggest that that Anavex 2-73 improves all of these measures, and it could be used against more Rett syndrome symptoms. These trials were also sponsored by Rettsyndrome.org
Steven Kaminsky, PhD, Chief Science Officer of Rettsyndrome.org, stated: “Success in the Phase 2 clinical trial could result in a truly safe and effective drug for this patient population, for which no effective treatment currently exists. We are very motivated to support this trial financially and by involving our knowledgeable clinical and educated community network.”
Christopher U. Missling, CEO of Anavex said: “We are delighted to continue our partnership with Rettsyndrome.org and its network of experts to accelerate the clinical development of ANAVEX 2-73 for the treatment of Rett syndrome.”
Anavex received Orphan Drug Designation from the U.S. Food and Drug Administration’s (FDA) for ANAVEX 2-73 in Rett syndrome on May 18, 2016.
